Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138800281> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2138800281 endingPage "6771" @default.
- W2138800281 startingPage "6767" @default.
- W2138800281 abstract "Abstract On March 15, 2005, the U.S. Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Five hundred seventy-three glioblastoma multiforme patients were randomized to receive either temozolomide + radiotherapy (n = 287) or radiotherapy alone (n = 286). Patients in the temozolomide + radiotherapy arm received concomitant temozolomide (75 mg/m2) once daily for the duration of radiation therapy (42-49 days). This was followed, 4 weeks later, by six cycles of temozolomide, 150 or 200 mg/m2 daily for 5 days, every 4 weeks. Patients in the control arm received radiotherapy only. In both arms, radiotherapy was delivered as 60 Gy/30 fractions to the tumor site with a 2 to 3 cm margin. Pneumocystis carinii pneumonia prophylaxis was required during temozolomide + radiotherapy treatment and was continued until recovery of lymphocytopenia (Common Toxicity Criteria grade <1). At disease progression, temozolomide salvage treatment was given to 161 of 282 patients (57%) in the radiotherapy alone arm, and to 62 of 277 patients (22%) in the temozolomide + radiotherapy arm. Patients receiving concomitant and maintenance temozolomide + radiotherapy had significantly improved overall survival. The hazard ratio was 0.63 (95% confidence interval, 0.52-0.75; log-rank, P < 0.0001). Median survival was 14.6 months (temozolomide + radiotherapy) versus 12.1 months (radiotherapy alone). Adverse events during temozolomide treatment included thrombocytopenia, nausea, vomiting, anorexia, constipation, alopecia, headache, fatigue, and convulsions." @default.
- W2138800281 created "2016-06-24" @default.
- W2138800281 creator A5051520990 @default.
- W2138800281 creator A5057752378 @default.
- W2138800281 creator A5070547422 @default.
- W2138800281 date "2005-10-01" @default.
- W2138800281 modified "2023-10-03" @default.
- W2138800281 title "Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme" @default.
- W2138800281 cites W1968704628 @default.
- W2138800281 cites W2019927904 @default.
- W2138800281 cites W2020898358 @default.
- W2138800281 cites W2088925558 @default.
- W2138800281 cites W2096287682 @default.
- W2138800281 cites W2139008103 @default.
- W2138800281 cites W2154451644 @default.
- W2138800281 cites W2167713837 @default.
- W2138800281 cites W2170129724 @default.
- W2138800281 cites W2264385870 @default.
- W2138800281 doi "https://doi.org/10.1158/1078-0432.ccr-05-0722" @default.
- W2138800281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16203762" @default.
- W2138800281 hasPublicationYear "2005" @default.
- W2138800281 type Work @default.
- W2138800281 sameAs 2138800281 @default.
- W2138800281 citedByCount "179" @default.
- W2138800281 countsByYear W21388002812012 @default.
- W2138800281 countsByYear W21388002812013 @default.
- W2138800281 countsByYear W21388002812014 @default.
- W2138800281 countsByYear W21388002812015 @default.
- W2138800281 countsByYear W21388002812016 @default.
- W2138800281 countsByYear W21388002812017 @default.
- W2138800281 countsByYear W21388002812018 @default.
- W2138800281 countsByYear W21388002812019 @default.
- W2138800281 countsByYear W21388002812020 @default.
- W2138800281 countsByYear W21388002812021 @default.
- W2138800281 countsByYear W21388002812022 @default.
- W2138800281 countsByYear W21388002812023 @default.
- W2138800281 crossrefType "journal-article" @default.
- W2138800281 hasAuthorship W2138800281A5051520990 @default.
- W2138800281 hasAuthorship W2138800281A5057752378 @default.
- W2138800281 hasAuthorship W2138800281A5070547422 @default.
- W2138800281 hasConcept C126322002 @default.
- W2138800281 hasConcept C141071460 @default.
- W2138800281 hasConcept C2776694085 @default.
- W2138800281 hasConcept C2777389519 @default.
- W2138800281 hasConcept C2779384505 @default.
- W2138800281 hasConcept C2780580376 @default.
- W2138800281 hasConcept C2780964509 @default.
- W2138800281 hasConcept C509974204 @default.
- W2138800281 hasConcept C71924100 @default.
- W2138800281 hasConceptScore W2138800281C126322002 @default.
- W2138800281 hasConceptScore W2138800281C141071460 @default.
- W2138800281 hasConceptScore W2138800281C2776694085 @default.
- W2138800281 hasConceptScore W2138800281C2777389519 @default.
- W2138800281 hasConceptScore W2138800281C2779384505 @default.
- W2138800281 hasConceptScore W2138800281C2780580376 @default.
- W2138800281 hasConceptScore W2138800281C2780964509 @default.
- W2138800281 hasConceptScore W2138800281C509974204 @default.
- W2138800281 hasConceptScore W2138800281C71924100 @default.
- W2138800281 hasIssue "19" @default.
- W2138800281 hasLocation W21388002811 @default.
- W2138800281 hasLocation W21388002812 @default.
- W2138800281 hasOpenAccess W2138800281 @default.
- W2138800281 hasPrimaryLocation W21388002811 @default.
- W2138800281 hasRelatedWork W2026096486 @default.
- W2138800281 hasRelatedWork W2046461201 @default.
- W2138800281 hasRelatedWork W2081094155 @default.
- W2138800281 hasRelatedWork W2143080478 @default.
- W2138800281 hasRelatedWork W2361498120 @default.
- W2138800281 hasRelatedWork W2384322989 @default.
- W2138800281 hasRelatedWork W2390408846 @default.
- W2138800281 hasRelatedWork W3041579002 @default.
- W2138800281 hasRelatedWork W4212846356 @default.
- W2138800281 hasRelatedWork W92501227 @default.
- W2138800281 hasVolume "11" @default.
- W2138800281 isParatext "false" @default.
- W2138800281 isRetracted "false" @default.
- W2138800281 magId "2138800281" @default.
- W2138800281 workType "article" @default.